Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regulators need patient-centric approach to obesity drug reviews

This article was originally published in Scrip

Executive Summary

Obesity-focused stakeholders are calling on regulators to take a more patient-centric approach when evaluating the benefits and risks of obesity drugs. The George Washington University (GWU) School of Public Health and Health Services has published Obesity drug outcome measures, a report detailing the consensus of findings from a stakeholder dialogue group, convened by the university, outlining a series of new approaches that should be considered by regulators when looking at obesity drugs.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC018463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel